Live Breaking News & Updates on Global Score

Stay updated with breaking news from Global score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Gantenerumab does not slow cognitive decline in early Alzheimer's

1. In these two randomized parallel-group trials, the use of gantenerumab did not lead to slower cognitive decline over 116 weeks among persons with early symptomatic Alzheimer’s disease compared to placebo. 2. After 116 weeks, gantenerumab was associated with lower amyloid plaque burden than the placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The accumulation ....

Minute Medicine Inc , Rating Level , Early Alzheimer , Clinical Dementia Rating , Global Score , Confidence Interval , Alzheimer 039 S , Alzheimers Disease , Amyloid Plaque , Chronic Disease , Cognitive Decline , Early Alzheimer 039 S ,